Similar Median OS Between Ripretinib versus Sunitinib in Patients with Advanced GIST While Safety More Favourable for Ripretinib By Ogkologos - June 2, 2025 865 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the final overall survival and updated safety analysis of the INTRIGUE study Source RELATED ARTICLESMORE FROM AUTHOR Giredestrant plus everolimus prolongs PFS among patients with ER-positive, HER2-negative, ESR1-mutated advanced breast cancer after the receipt of a CDK4/6 inhibitor EMA Recommends Granting a Marketing Authorisation for Ensartinib Taking on the RAS Challenge MOST POPULAR Qué saber sobre los diferentes tipos de mastectomías para el cáncer... November 15, 2023 Cancer Clinical Trials Bounce Back After Significant COVID-19 Disruption: Data From... June 15, 2022 Breast Cancer Survivor’s Family Designs a Holiday Light Show in Her... December 15, 2020 ESMO Raises Key Issues on Cancer Prevention and Care at the... January 21, 2026 Load more HOT NEWS Mezigdomide-Carfilzomib-Dexamethasone Prolongs PFS Compared with Carfilzomib-Dexamethasone at First Relapse in Patients... Weekly Cisplatin-Based Chemoradiotherapy Improves RFS and OS, Although Not Statistically Significant,... Mom Is Warning Other Parents After Her Son Was Bit By... Man Offers Free Lawn Mowing Service To Elderly And Veterans
